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ABSTRACT 
The pharmaceutical industry of Bangladesh is now meeting around 97% of total domestic demand with an annual 
two digit growth rate. But the question arises as to whether the firms produce efficiently? The paper measures 
technical efficiency of the pharmaceutical industry of Bangladesh using Data Envelopment Analysis (DEA) over a 
period of 2009 to 2013. We use the non-parametric DEA with one output- annual sales and three inputs; viz. (i) 
fixed asset; (ii) raw material cost; and (iii) cost of salary. Results of the analysis reveal that Malmquist total factor 
productivity index (TPI) has maintained a slightly upward trend during the study period with a value of 4.7% 
annually. It has also been observed that the major contributor of TPI growth is technological change with a value of 
10.8% positive growth annually. Additionally, all changes of technical efficiency; pure efficiency and scale 
efficiency have regressed with values of 5.5%, 2.1% and 3.5% respectively. The overall productivity progress was 
due to technological progress and an overall efficiency regress. Thus, the gains in productivity are entirely due to 
technological advancements, and not efficiency improvement. The main source of inefficiency in pharmaceutical 
industry is scale inefficiency rather than pure technical inefficiency. 
Keywords: Efficiency; Data Envelopment Analysis; Malmquist Productivity Index; Pharmaceutical. 
INTRODUCTION 
Since independence in 1971, Bangladesh has faced multidimensional challenges in the way to economic 
development and sustainability. Ensuring productivity is one of them and has also been neglected earlier. 
The early 1990s witnessed the start of first industrialization of major industries. Pharmaceutical industry 
growth was an exception. A two digit annual growth has made this sector important in the economy. 
Currently, almost all domestic demand is met with endogenous production except latest innovations and 
rare cases. Many published articles and news headlines supported the view that the industry has grown 
faster than others. But the fact is growth in sales does not necessarily mean that the industry is operating 
efficiently. Authors identified a literature gap. That is, does the industry run in an efficient way? This 
study analyzed technical efficiency (TEC) of Bangladeshi pharmaceutical industry. We used output-
oriented Malmquist index to answer the following questions: a) among the companies who are the major 
contributors of the total factor productivity growth in Bangladesh from 2009 to 2013? b) how is the trend 
of technological changes in selected companies over the period covered? 
This paper has five sections. The following section describes a brief background of pharmaceuticals 
industry in Bangladesh. Section III presents the method of the study, data source and model development 
for the analysis. Section IV addresses major contribution of earlier literature in the above issues. Analysis 
of empirical results is discussed in section V. Finally, section VI presents conclusion and policy 
implications. 
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BACKGROUND OF THE PHARMACEUTICAL INDUSTRY OF BANGLADESH 
The progress record of this industry is very pleasing. In 1982, Government of Bangladesh deregulated the 
Drugs Control Ordinance. It helped local investors to jump into investment. Before that, Bangladesh was 
completely an import oriented country. Nowadays, roughly 343 pharmaceutical companies are registered 
to serve a market of USD 1300 million (Hossain, Nur, & Habib, 2014).  According to the report of The 
Dhaka Chamber of Commerce and Industries (DCCI), Bangladesh pharmaceutical industry is self-
sufficient in meeting 97% of local demand. Remaining 3% consist of specialized vaccines and anti-cancer 
products. This industry is now the second largest contributor of national revenue from exporting a wide 
range of medicine to more than 75 countries around the globe. Most importantly, the industry is 
dominated by the local companies. Besides creating employment, this promising sector recently attracted 
foreign investment by offering three main competitive advantages; a) reasonable power cost, b) low labor 
cost and c) trained employee (white color labor) cost. Since liberation in 1971, in just four decades, a full-
fledged industry is now operating with pride. 
However, the agreement between Bangladesh and Trade Related Aspects of Intellectual Property Rights 
(TRIPS) in 2001 prescribes that Bangladesh can enjoy purchase of  raw materials without patent fees as 
the member of Least Development Country (LDC) and World Health Organization (WHO) until 2016. 
During this period, Bangladesh is also imposed with restricted export facility. Now, a deeper look may 
find the gravity of requiring an answer to a question, that is, did the industry achieve efficiency? The 
improvement we saw is not all, indeed. It is important to study the sources of the productivity within the 
industry. The results from the study would help executives, government and policy makers to reshape 
their strategies and aid policy decisions. 
METHODS 
Malmquist total factor productivity (TPI) is used in the study to measure performance of Bangladeshi 
pharmaceuticals industry.  Literally, efficiency measurement begins with the valued work of (Debreu, 
1951) where “dead loss” of an economic system was numerically evaluated in a non-optimal economic 
condition. Later, efficiency was first introduced by (Koopmans, 1957). His definition of technical 
efficiency explains output maximization capacity keeping input constant or minimizing input keeping 
output level unchanged. The Malmquist index is used to present efficiency of a DMU over a period of 
time. Based on the valued work of (Malmquist, 1953), (Caves, Christensen, & Diewert, 1982) and 
improved the non-parametric framework of Malmquist index. Total factor productivity (TPI) of a firm 
was first proposed by (Coelli, Rao, O'Donnell, & Battese, 2005). They estimated an index contained with 
all inputs and outputs of a DMU in ratio format. Non-parametric distance function is used for the 
calculation. Use of distance function is due to examine the relative status of a DMU in comparison to the 
optimal DMU at a given set of inputs and outputs. Benefits of using TPI are ability of using multiple 
outputs and inputs along with no requirement of specifying behavioral objective functions. Compared to 
“Tornqvist and Fisher” model, TPI does not require input price for productivity calculation. In addition, 
Byproducts of TPI are technical efficiency change (TEC) and technical change (TCH). Again, TEC can 
be said as product of scale efficiency (SE) and pure efficiency (PU). These sources of efficiency changes 
help researchers for examining efficiency from different perspectives. Furthermore, the decomposition of 
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TPI helps in further modeling and innovation of efficiency analysis. (Fare, Grosskopf, Norris, & Zhang, 
1994) demonstrate the use of DEA for calculating TPI index. Based on the CCR ratio, (Banker, Charnes, 
& Cooper, 1984) examined a model using multiple inputs and outputs in all capacity (Increasing, constant 
or decreasing return to scale) of firms. Their findings contributed modern economics in farther 
exploration. 
If the input and output vector of a production unit is presented by 𝑥𝑡𝑎𝑛𝑑 𝑦𝑡and (t) stands for time period, 
the output set of the production process can be defined as: 
𝑃𝑡(𝑋𝑡) = {𝑌𝑡: 𝑋𝑡  𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑠 𝑌𝑡}        (1) 
This output set by Chou, Shao, and Lin (2012) satisfies notion of disposability of inputs and outputs since 
it assumed to be closed, bounded and convex (Coelli et al., 2005). A distance function for the output set 
can be designed as follow: 
𝐷𝑡(𝑥𝑡, 𝑦𝑡) = min {𝜃: (𝑦𝑡 𝜃)⁄  ∈  𝑃𝑡(𝑥𝑡)}       (2) 
Note that, the input oriented distance function is just the reciprocal of Eq. (2). Again, 𝜃 stands as radial 
factor for adjusting output vector’s position. Since the boundary of (x,y) is defined as the set of (𝜃)= (1,1), 
Eq. (2) corresponds to BBC (variable returns to scale) models. We can duplicate eq. (2) as a linear 
programming (LP) converting   for a DMU t’ 
(𝐷 (𝑥𝑡’, 𝑦𝑡’))
−1
= max { 𝜆: ∑𝑧𝑡𝑥𝑡𝑛 ≦ 𝑥𝑡’𝑛,       𝑛 = 1………𝑁
𝑇
𝑡=1
 
∑𝑧𝑡𝑦𝑡𝑚 ≧ 𝑥𝑦𝑡’𝑚,       𝑚 = 1………𝑀
𝑇
𝑡=1
 
𝑧𝑡 ≦ 0, 𝑡 = 1……… . . 𝑇}                                                                               (2.1) 
Here, 𝑧𝑡 is the intensity variable. 
Considering two consecutive time frames e.g. t and t+1, and combining the distance function of Eq. (2), 
TPI of Malmquist index can be shown as follow:  
 𝑀𝐼 (𝑦𝑡, 𝑥𝑡 , 𝑦𝑡+1, 𝑥𝑡+1) = [ 
𝐷𝑡(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
×
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡+1(𝑥𝑡,𝑦𝑡)
]
1
2
      (3) 
Eq. (3) can be transformed into; 
 𝑀𝐼 = [
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
] [ 
𝐷𝑡(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
×
𝐷𝑡(𝑥𝑡,𝑦𝑡)
𝐷𝑡+1(𝑥𝑡,𝑦𝑡)
]
1
2
     (4) 
Here, 
𝑇𝑒𝑐ℎ𝑛𝑖𝑐𝑎𝑙 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 (𝑇𝐸𝐶) = [
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
]     (5) 
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𝑇𝑒𝑐ℎ𝑛𝑖𝑐𝑎𝑙 𝐶ℎ𝑎𝑛𝑔𝑒 (𝑇𝐶𝐻) = [ 
𝐷𝑡(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
×
𝐷𝑡(𝑥𝑡,𝑦𝑡)
𝐷𝑡+1(𝑥𝑡,𝑦𝑡)
]
1
2
     (6) 
So, 𝑀𝑎𝑙𝑚𝑞𝑢𝑖𝑠𝑡 𝑇𝑃𝐼 = 𝑇𝐸𝐶 × 𝑇𝐶𝐻        (7) 
Output oriented Malmquist TPI Index, as shown above in Eq. (3) can be decomposed as a product of 
technical efficiency change (TEC) and technical change (TCH) as presented in Eq. (4). Keeping the input 
vector constant for the period t, the distance function explains the major changes until the period t+1. 
Here, D is used as distance function by taking the decision-making unit in the assessment to desired 
frontier. In Eq. (3), the first part of the ratio (
𝐷𝑡(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
) expresses the concept of Catch-Up and the 
second part (
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡+1(𝑥𝑡,𝑦𝑡)
) denotes Frontier Shift of the DMU from time t to t+1 (Cooper, Seiford, & Tone, 
2007, p. 329). The frontier shift assumes the first part as the target benchmark and captures the technical 
efficiency changes for the following period. In order to calculate productivity changes of a DMU, at least 
two frontiers must be considered. A value of MI more than one defines productive growth and less than 
one indicates productivity decline in a given adjacent time. The specialty of MI is it can decompose 
productivity change of the required frontier into two exclusive components; TEC and TCH 
(Davamanirajan, Kauffman, Kriebel, & Mukhopadhyay, 2006).  Noted that, a value of 1 (one) for all TPI, 
TEC and TCH explains that the company efficiency remains equal compared to period (t) in (t+1). Again, 
a value of more than 1 (one) represents improvement and less than 1 (one) explains regress in efficiency 
as a relative measure. 
Further decomposition of TEC, Eq. (5) is shown below: 
𝑇𝐸𝐶 = [
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
]  
= [
𝐷𝑉𝑅𝑆
𝑡+1 (𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑉𝑅𝑆
𝑡 (𝑥𝑡,𝑦𝑡)
] [ 
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
×
𝐷𝑉𝑅𝑆
𝑡 (𝑥𝑡,𝑦𝑡)
𝐷𝑉𝑅𝑆
𝑡+1 (𝑥𝑡+1,𝑦𝑡+1)
]      (8) 
Here, 𝐷𝑉𝑅𝑆 is the output distance function for variable returns to scale. The first part of the Eq. (8) is 
named as pure efficiency (PE) that describes pure change in technical efficiency in a relative form of 
defined consecutive time period. And, remaining part of Eq. (8) stands for describing change in effect due 
to economics of scale and denoted by SE. Thus, 
𝑃𝑢𝑟𝑒 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝐶ℎ𝑎𝑛𝑔𝑒𝑠 (𝑃𝐸) = [
𝐷𝑉𝑅𝑆
𝑡+1 (𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑉𝑅𝑆
𝑡 (𝑥𝑡,𝑦𝑡)
]      (9) 
𝑆𝑐𝑎𝑙𝑒 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒𝑠 (𝑆𝐸) = [ 
𝐷𝑡+1(𝑥𝑡+1,𝑦𝑡+1)
𝐷𝑡(𝑥𝑡,𝑦𝑡)
×
𝐷𝑉𝑅𝑆
𝑡 (𝑥𝑡,𝑦𝑡)
𝐷𝑉𝑅𝑆
𝑡+1 (𝑥𝑡+1,𝑦𝑡+1)
]    (10) 
Combining Eq. (4) and (8), it comes as TPI is the product of TCH, PE and SE. An extended version of 
Eq. (7) can be then, 
 𝑀𝑎𝑙𝑚𝑞𝑢𝑖𝑠𝑡 𝑇𝑃𝐼 = 𝑃𝐸 × 𝑆𝐸 × 𝑇𝐶𝐻        (11) 
This study evaluates sources of efficiency changes in pharmaceuticals industry of Bangladesh using TPI. 
Three inputs have been selected for the analysis namely fixed asset, cost of raw materials and cost of 
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salary and wages with only one output namely sales (both local and export). Data is collected from annual 
reports published by the companies. Despite having 343 pharmaceuticals firms in the country, this study 
focuses on all the 14 companies listed in the stock exchange, due to unavailability of data. The study 
covers data from 2009 to 2013.  
LITERATURE REVIEW 
The measurement of efficiency in Bangladeshi Pharmaceuticals Industry would be the first of its nature. 
Past studies are mostly related to pharmaceutical industries covering various factors of production e.g. 
input, output, constraints etc.  Most of the literatures on manufacturing industry have been focused on 
output-oriented productivity viz. sales. A unit of positive change in output indicates a unit increase in the 
efficiency of inputs. Thus, reduction of input cost may meet by producing higher level of output. This 
paper covers the literature only on efficiency, productivity of pharmaceuticals and manufacturing industry 
and Total Factor Productivity.  
Both Azam and Richardson (2010) and Royhan (2013) concentrated on present status and future prospect 
of Bangladeshi pharmaceutical industry. Their findings have limitation in proper justification of the 
growth statement and model specification. Saranga and Phani (2004) examined DEA of Indian 
pharmaceutical companies using data from 44 listed companies. Authors argued that the growth of 
individual company is independent to its internal efficiency. They suggested for a preparation of being 
“product patent” rather “process patent”. According to them, earlier realization of world scenario in 
pharmaceutical industry and action plan can save the total industry in case of major external economic 
and international crisis. Mazumdar and Rajeev (2009) evaluated comparative efficiency of different 
Indian Pharmaceutical companies. They examined data from 2492 unbalanced firms over a period of 
1991-2005. The study has revealed that positive technical efficiency changes have been observed in the 
companies with large-sized and import orientation of new innovation. Investment in R&D has been found 
as poorly contributing component in Total Factor of Productivity growth among the selected companies. 
Kirigia, Emrouznejad, Sambo, Munguti, and Liambila (2004) analyzed technical efficiency of health 
organizations in Kenya. Based on the secondary data from 32 major health care centers, DEA has been 
examined. Their findings have revealed that 44% of total health care center are technically inefficient. 
Seminal paper of Hashimoto and Haneda (2008) has been examined technical efficiency of Japanese 
pharmaceutical industry using same technique. They used sales volume as single output and three inputs 
namely, patent or R&D, product innovation and process innovation cost. Their findings have been 
summarized a consistent negative productivity change over the period of 1982 to 2001. Recently,  
Tripathy, Yadav, and Sharma (2013)  examined 81 Indian pharmaceutical companies using Malmquist 
productivity index. A positive technical efficiency change has been observed over the period of the 
observation. The study has resulted with significant outcomes in determining firm-specific factors of 
productivity for any pharmaceutical company. For example; age of establishment, Research and 
development, ownership and foreign direct investment.  
Nordin Haji Mohamad and Said (2011) measured efficiency of Government linked Malaysian companies 
using data from 2003 to 2008. DEA analysis identified only 10 companies in the favorable frontier. 
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Malmquist index of TPI examined that even though the companies have shown a positive technical 
efficiency change in the results but did not achieve recommending technological change of new 
innovations and progress. This study has used Paid-up-capital, Fixed Asset and Total Salary as input and 
Sales revenue, Return on Asset and Market Price per share as output. A recent work of Ramli and 
Munisamy (2013) on technical efficiency and ecological efficiency also contributed the existing literature.  
They applied DEA and Directional Distance Function (DDF) on manufacturing industries over the period 
of 2001 to 2010.  The study has used Operating Expenditure and Capital as input and sales as desirable 
output. In contrast to the findings of Jajri and Ismail (2007), Ramli and Munisamy (2013) checked the 
efficiency on state basis rather than sector basis. 
Noordin Haji Mohamad and Said (2012)studied on efficiency measurement of 42 world economies on 
effect of technology innovation had revealed that only best practiced firms can adopt and make use of 
new technological adoption at higher rate rather than others. Decomposition of TPI also suggested that 
there was no significant difference in efficiency changes compared to technological innovation in 
economy. Authors argued that a positive unit TPI change can maximize the level of output and shift the 
economy at higher frontier. Looking at the size orientation and productivity of firms, Schiersch (2012) 
filled the gap of size-efficiency relationship studying more than 22,023 observations of German 
mechanical engineering industry. Study revealed that comparatively small and large companies are 
efficient ones and medium ones are mostly inefficient. Their findings also suggested that a U-shaped 
relationship has been observed in case of size-efficiency relationship unlike the simple increasing shape 
found in earlier studies. Worldwide, a big number of researches have been conducted using DEA to test 
TPI growth. Mahadevan (2002) tested TPI of Malaysian manufacturing industries from 1981 to 1996. 
Technical efficiency and scale efficiency have been analyzed and found a positive growth scoring 0.8% 
annually. Literature supported that this poor change has been driven by technological changes. Din, 
Ghani, and Mahmood (2007) examined the efficiency of Pakistani large-scale manufacturing industry. 
They used both parametric and non-parametric frontier techniques. They covered data between 1995 and 
2001. Only a little increase in efficiency level has been observed in both results. The study used Capital 
and Labor as input and Industrial and non-industrial cost as output. Here, industrial cost explains 
operating cost and Non-industrial cost contains intangible and non-operating costs.  
Overtime, a growing concern has been observed in Total Factor Productivity growth calculation for 
efficiency measurement. Kartz (1969) argued that technological changes and innovation have a 
significant role in productivity changes. His study covered TPI in Argentina over the period of 1946 to 
1961 and identified improvement in labor productivity in manufacturing sector. Jajri and Ismail (2007) 
calculated the efficiency of Malaysian manufacturing sector over a period of 1985 to 2000 using Data 
Envelopment Analysis (DEA) technique with two inputs; labor and capital expenditure (Fixed Asset), and 
a single output i.e. value added sales price. Their findings suggested that technical efficiency is the major 
contributor in Total Factor Productivity. An upward trend of technological change was also highlighted 
except in the textile industry. Most of the empirical studies on efficiency management have revealed that 
efficiency of pharmaceuticals industry is in positive relation with size, good governance, technological 
innovation and business nature (Anesary et al., 2014; Mazumdar & Rajeev, 2009; Saranga & Phani, 
2004). Poor relationship has been identified between geographical region, model of analysis, time frame 
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and efficiency (Azam & Richardson, 2010; Centre, 2007; Hossain et al., 2014). In line with this, present 
study attempts to explore the case of Bangladeshi Pharmaceuticals industry. 
RESULTS AND DISCUSSION 
Table 1 and 2 explain efficiency scores of all 14 selected pharmaceutical companies over the  period 2009 
to 2013. Based on Malmquist index analysis proposed by (Fare et al., 1994), productivity of a decision 
making unit is evaluated based on the value of one. A value more than unity explains the positive TPI 
growth of that decision making unit (DMU) for the time (t+1) compared to time (t).  
Table 1: Malmquist index summary of annual means (2009- 2013) 
year TEC TCH PE SE TPI 
2009 0.944 1.266 1.022 0.924 1.196 
2010 0.761 1.347 0.926 0.822 1.024 
2011 0.877 1.151 0.755 1.161 1.009 
2012 1.427 0.696 1.319 1.081 0.994 
2013 0.838 1.225 0.954 0.879 1.027 
mean 0.9694 1.137 0.9952 0.9734 1.050 
Table 1 represents a summary of annual means of Technical Efficiency Change, Technological Change, 
Pure Technical Efficiency Change, Scale Technical Efficiency Change and Total Factor Productivity 
(TPI) Change for all 14 companies. It is seen from the table that all the companies have inefficiency 
within a range of 5.6% to 23.9% in case of Technical Efficiency Change throughout the study period 
except for the year 2012. In case of Technological Change, all companies have experienced a negative 
efficiency of 31.4% in the same year. Compared to other years, this deficiency is a major breakdown. 
Even though, in the following year, companies have restored the capacity and had a 22.5% upward TPI 
growth. Turning to pure technical efficiency; companies have experienced a positive growth change in 
2009 and 2012. In remaining years, negative efficiency within a range of 4.6% to 24.5% has been 
witnessed in the table. A similarly mixed result has also been observed in case of Scale Efficiency Change 
of the companies over the study period. Looking at the means, the main source of technical inefficiency in 
pharmaceutical industry is scale inefficiency rather than pure technical inefficiency. In total, the Total 
Factor Productivity (TPI) growth of the companies found to be positive except for the year 2012 and 
within a range of -0.6% to +19%. The overall TPI growth change of the companies is in the order of 4.7% 
over the study period. 
Figure 1 depicts the line graph of technical efficiency, technological change and total factor productivity 
(TPI). The most noticeable criteria are TEC and TCH have followed an inverse pattern throughout the 
study period.  It is also highlighted here that for both of the trends, the most disruption is occurred in the 
year 2012. In aggregate, a regress in TPI is observed from 2009 to 2012 mainly due to consistent fall in 
TCH.  Results of table 1 present a significant influence of TCH over TPI. 
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Figure 1: Changes in TEC, TCH and TPI over the study period (2009-2013) 
Figure 1 depicts the line graph of technical efficiency, technological change and total factor productivity 
(TPI). The most noticeable criteria are TEC and TCH have followed an inverse pattern throughout the 
study period.  It is also highlighted here that for both of the trends, the most disruption is occurred in the 
year 2012. In aggregate, a regress in TPI is observed from 2009 to 2012 mainly due to consistent fall in 
TCH.  Results of table 1 present a significant influence of TCH over TPI. Similar research on MI and TPI 
of (Ahn & Min, 2014; Arjomandi, Valadkhani, & O’Brien, 2014) explain the attachment of TCH with 
macroeconomic factors e.g. government policy or restrictions, country specific issues and financial 
stability and advancement in technology within the industry. Results from the table 1 explain an 
opportunity of further improvement in TPI is attached with the degree of adoption capacity of the industry 
with macro-economic external business environment and changes. Moreover, Bangladesh has faced some 
economic slowdown in mid of 2012 (Aziz, Janor, & Mahadi, 2013).  It is of course a matter of discussion 
that what factors may effect on technological changes and by how much?  
Table 2 reveals a nutshell of Malmquist Index Summary of Firm Means which is based on geometric 
means over a period of 2009 to 2013. As noted previously, the TPI of all companies observed a positive 
growth of 4.7% annually. This change could be higher if Technical Efficiency Change of companies were 
somewhere in unit value or positive values. On average, a total 5.5% negative efficiency has been seen in 
Technical Efficiency Change of all companies annually. ACI, GLAXOSMITH and RENATA had unit 
efficiency change annually. Only RECKITTBEN had a positive Technical efficiency change with a value 
of 3.3% annually among the companies. A total of 9 (nine) companies, however, experienced a positive 
change in technological efficiency with a range of 5.3% to 36% annually. And 5 (five) companies namely 
AMBEEPHA, CENTRALPHL, MARICO, ORIONPHARM and RECKITTBEN have been found 
inefficient over the study period. Considering Technological change, all the companies have scored, on an 
average, 10.8% positive growth annually. Inefficiency has been observed in both pure technical efficiency 
and scale efficiency scoring of about 3% annually. Based on the findings, it is to be recorded that a total 
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of 9 companies have been observed with positive Total Factor Productivity (TFP) growth changes. 
Among them, ACI, GLAXOSMITH and RENATA have been found top ranked.  Remaining 5 companies 
have scored negatively in TPI change with a range of -1.1% to 28.6% annually. The lowest and highest 
TPI changes have been observed for AMBEEPHA and ACI respectively. 
Table 2: Malmquist index summary of firm means (2009- 2013) 
Firm TEC TCH PE SE TPI 
ACI( ACI Limited. ) 1.000 1.360 1.000 1.000 1.360 
AMBEEPHA( Ambee Pharma ) 0.917 0.778 0.993 0.923 0.714 
BEACONPHAR( Beacon Pharma. Ltd. ) 0.866 1.358 0.880 0.984 1.176 
BXPHARMA( Beximco Pharma ) 0.936 1.214 1.000 0.936 1.136 
CENTRALPHL( Central Pharma. Ltd. ) 0.939 1.053 0.963 0.975 0.989 
GLAXOSMITH( Glaxo SmithKline ) 1.000 1.300 1.000 1.000 1.300 
IBNSINA( The Ibn Sina ) 0.940 1.180 0.941 1.000 1.110 
LIBRAINFU( Libra Infusions Limited ) 0.976 1.085 0.984 0.992 1.059 
MARICO( Marico Bangladesh Limited ) 0.917 0.855 0.993 0.923 0.784 
ORIONPHARM( Orion Pharma Ltd. ) 0.878 1.075 0.915 0.959 0.943 
PHARMAID( Pharma Aids ) 0.932 1.128 1.000 0.932 1.051 
RECKITTBEN( Reckitt Ltd. ) 1.033 0.951 1.054 0.980 0.982 
RENATA( Renata Ltd. ) 1.000 1.245 1.000 1.000 1.245 
SQURPHARMA( Square Pharma. Ltd. ) 0.915 1.123 1.000 0.915 1.028 
Geometric Mean 0.945 1.108 0.979 0.965 1.047 
The geometric mean of TEC, PE and SE has significance.  In this part we will highlight the main sources 
of inefficiency in pharmaceutical industry. As discussed earlier, TEC can be decomposed into PE and SE. 
In table 2, 2.1% of overall pure inefficiency is described by the overall technical inefficiency of 5.5%. 
This surely means that the internal management of the selected companies is responsible for such 
inefficiency. And the remaining inefficiency of TEC is described by scale efficiency which means there is 
a possibility of been performing inefficiency just because of sub-optimal scale size. Out of 14 firms, equal 
numbers of firms are in best practice frontier and in inefficient area. In case of SE, a value of 1 denotes 
company’s presence in the line of long term average cost curve. SE value of less than one explains the 
firms’ inability of run with appropriate size and direct relation with technical inefficiency. Among the 14 
firms, only 3 (three) companies are in most productive scale size scoring with value with one. Remaining 
companies have scale inefficiency from a range of .08% to 8.5%.  
CONCLUSIONS 
This study has contributed the literature by filling a gap between the knowledge of existing industry 
growth and its true productivity. The findings have indicated an average positive productivity change in 
Bangladeshi pharmaceutical industry over the study period from 2009 to 2013. Results from the model 
explain the marginal productivity improvement is only due to technological changes of the industry 
through the adoption and development of new technological aspects within the companies. The overall 
technical efficiency has regressed. The decline in efficiency is likely to be due to the widening of the 
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efficiency gap among pharmaceutical with less efficient companies moving further away from the 
frontier. The reasons for the increased dispersion of performance are not apparent but may indicate 
several things. The dispersion may be due to the strong influence of external environment e.g. in 2012, 
there was political unrest in Bangladesh; export limitations imposed by TRIPS; barriers to diffusion of 
innovation and the absence of successful mergers and acquisitions among the inefficient companies. The 
latter indicates that efficient reorganization is not taking place in the industry.  
It is seen that a majority of the big pharmaceutical companies in Bangladesh are experts in process patent 
activities rather in product patent. Such industry condition can easily generate higher profile in production 
and sales. However, achieving sustainability in long run using automation and purchase of patent may not 
be possible. In over the last two decades, it is found that both medium and big size companies have leaned 
on introducing automation in their existing product plants, improving them in nothing but production. 
Even though, with such increase of production and sales, the cost for production did not change 
significantly. Apart from this, Bangladesh can only enjoy the special facility on raw materials import at 
reduced price until 2016. Post 2016, Bangladesh must pay at least 40% extra compared to the present cost 
for this purpose. Existing literature supports that only two companies have been investing on research and 
development on patent development and raw material production. Major researches show that 
establishing sustainability and productivity of pharmaceutical companies depend on “Product Patent” 
rather than “Process Patent”. Without establishing self-dependency on production and innovation of raw 
materials, this bright manufacturing sector may face absolute shock in next short time.  
The convergence of efficiency towards the frontier can be achieved by learning the practices of peer units, 
strengthening incentive schemes to improve efficiency, controlling the reorganization of the industry, 
removing barriers to exporting, and stimulating research and innovation. 
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